Read Article

Supporting international business matching, LSMIP propritizes "Speed" and "Accuracy" in out service.
Please be noted that contents are in English/Japanese, translated on a request basis from authors/members.
国際間のビジネス・マッチングを促進するため、LSMIPでは情報発信の迅速性・正確性を重視しております。
コンテンツは各言語(英語、日本語)でお読みいただけますが、必要に応じて翻訳する場合があります。

Overview

0

[Yakuji Nippo]Pharmaceutical Production Value Is 9.5 Trillion Yen - Saitama Prefecture Is Top Producer

The Ministry of Health, Labour and Welfare (MHLW) has released the "Annual Report on the Statistics of Production by Pharmaceutical ...
  • Target market
    Japan
  • Business category
    Pharmaceutical, Biopharmaceutical, Regerative medicine, Medical device, Digital health, Others
  • Business function
    Marketing >
  • Keyword
  • Author
    "LSMIP Editorial Office" of "CM Plus Corporation"
  • Availability
    Membership

Detail


株式会社薬事日報社から許諾を受けて、株式会社シーエムプラスが英語に翻訳しております。
オリジナルの正式言語は日本語であり、内容および解釈については日本語が優先されます。
With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

 

【MHLW】
Pharmaceutical Production Value Is 9.5 Trillion Yen - Saitama Prefecture Is Top Producer

January 15th, 2021

The Ministry of Health, Labour and Welfare (MHLW) has released the "Annual Report on the Statistics of Production by Pharmaceutical Industry" for 2019. The domestic production value of pharmaceuticals increased by 37.3% year-on-year to 9.486 trillion yen. In terms of production value by prefecture, Saitama Prefecture rose to the top from the sixth place the previous year. The production value of regenerative medical products, which was surveyed for the first time, was 5.5 billion yen. The MHLW says that the results of this year's survey show an increase or decrease from those of the previous year due to a change after a review of the survey methodology, including limitation of survey objects to manufacturing and sales offices.
 

(Continue to the next)


For this translated article in English, CM Plus Corporation shall have the copyright.
Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2021 LSMIP office / CM Plus Singapore Pte. Ltd.

Comments (Require approval)

What information are you looking for in articles?
Let us help you to find out the articles for your business requirements!
Like many other companies, we use cookies and other technologies, some of which are essential to make our website work. By clicking Accept or continuing to use our site, you agree to use these cookies and other technologies. To learn more, check out our privacy policy.
Accept